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Abstract
The emergency medicine (EM) and prehospital environments are unlike any other clinical environments
and require special consideration to allow the successful implementation of clinical trials. This article
reviews the specific issues involved in EM clinical trials and provides strategies from EM and non-EM
trials to maximize recruitment and retention. While the evidence supporting some of these strategies
is deficient, addressing recruitment and retention issues with specific strategies will help researchers
deal with these issues in their funding applications and in turn develop the necessary infrastructure to
participate in EM clinical trials.
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T he United States spends $2 trillion annually onhealth care, with as much as 15%–20% beingspent in acute care and emergency situations.1
Evidenced-based medicine is dependent on information
gained from well-run clinical trials to provide the
answers needed to guide efficient and cost-effective
patient care. Clear evidence is lacking for many treat-
ments, but research efforts are growing, especially in
emergency medicine (EM). Projects and funding for
research in this setting are not limited to the specialty of
EM, but often involve the collaboration of multiple spe-
cialties such as orthopedics, cardiology, pediatrics, and
neurology, both individually and as part of networks.
A recent search of ClinicalTrials.gov for ‘‘emergency
department’’ clinical trials resulted in 691 open and
closed studies, 312 currently seeking volunteers, and 59
that are listed as being funded by the National Institutes
of Health (NIH) or other U.S. federal agencies.2 A simi-
lar search of the Research Portfolio Online Reporting
Tool listed 153 new research grants in 2009 supported
by the NIH.3 There are several well-funded existing
emergency research networks, such as the Neurological
Emergencies Treatment Trials network (NETT) and
Resuscitation Outcomes Consortium (ROC), both fun-
ded by the NIH. The Pediatric Emergency Care Applied
Research Network (PECARN) is another emergency
network funded by the Health Resources and Services
Administration ⁄ Maternal and Child Health Bureau’s
Emergency Medical Services for Children Program and
Division of Research, Training, and Education.4–6 Both
the NETT and the ROC networks offer opportunities
for numerous locations to participate in clinical trials in
the emergency department (ED) setting; NETT has four
current projects and 17 centers, and ROC has four
current projects and 11 clinical centers (Table 1). The
PECARN network has four research centers, each with
multiple affiliated EDs, totaling 21 hospitals that serve
approximately 900,000 acutely ill and injured pediatric
patients annually.6 In addition, the National Institutes of
Neurological Disorders and Stroke (NINDS) has
launched the Clinical Research Collaboration, a project
designed to encourage academic- and community-
based neurologists and neurosurgeons to participate in
clinical research through access to multiple clinical
research protocols. Many of these protocols are rele-
vant to EM and will need collaboration from emergency
physicians to help enroll patients, such as those with
epilepsy, headaches, stroke, and transient ischemic
attacks.7
Essential to the success of any network is the recruit-
ment and retention of subjects into studies. Although
recruitment and retention may seem straightforward,
issues unique to the ED environment need to be consi-
dered. This article highlights these issues and dis-
cusses how to incorporate strategies into the study
design and one’s research infrastructure (Table 2).
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By understanding and addressing these issues, we hope
investigators can increase the likelihood of funding and
implement successful EM clinical trials.
THE SETTING
The most recent public data from 2006 show that the
volume of ED patients has increased by 36% over the
past decade, to approximately 120 million visits annu-
ally.8 This includes acute care and preventive care visits,
which comprise 20% of ED patients who are unable to
get an appointment with or do not have a primary care
provider.9 EDs are also the gateway for the sickest
patients who enter the hospital and health care system,
being responsible for about 20% of hospital admis-
sions.10 The crowding and volume seen in EDs make
them challenging environments to provide effective and
timely care, apart from trying to incorporate clinical
research.11,12
However, the challenges and funding of research in
the ED are being addressed. In addition to the NETT,
ROC, and PECARN networks, the introduction of the
Comparative Effectiveness Research Act of 2008 and
America’s Affordable Health Choices Act of 2009 puts
the focus on cost-effectiveness in all areas of health
care. Specifically, one of the top 100 Initial Priority Top-
ics for Comparative Effectiveness Research is investi-
gating the value of neurologic and orthopedic imaging
modalities when ordered by emergency physicians.13
Emergency medicine researchers will be called upon
more and more to participate in this type of research
and in turn will receive more funding to do research in
the ED. For researchers, particularly those not practic-
ing in the ED environment, it may be difficult to under-
stand why it is difficult to recruit and successfully
complete trials from the ED.14 Unlike the controlled
environment of a clinic or general clinical research cen-
ter, caregivers have neither the time nor the resources
to help with research. With this in mind, researchers
must optimize the design and implementation of trials
to accommodate the ED setting to take advantage
of the millions of ED patients who could be eligible to
participate in clinical trials.
RECRUITMENT
Providing evidence that one can enroll patients in the
numbers required is crucial to receiving funding. Pilot
studies can be done to determine the number of eligible
and ineligible patients.15,16 While pilot studies allow for
the most precise determination of potential subjects
and a preview of potential implementation problems,
they require a significant investment of resources for a
small number of participants and cannot be done prac-
tically without funding themselves. Prospective and ret-
rospective screening through chart review are more
practical and can be helpful to estimate recruitment
capabilities.17 However, these reviews often fail to iden-
tify potential obstacles to recruitment, such as real-time
identification of eligible participants, consent issues,
and the complexities of implementing a protocol. Once
investigators can demonstrate that participants are
Table 1






NETT Conduct large simple trials to
reduce the burden of very acute
injuries and illnesses affecting the
brain, spinal cord, and peripheral
nervous system and to improve
outcomes of patients with acute
neurologic problems through
innovative research focused on








ROC Clinical trial network focusing on
research in the area of
prehospital cardiopulmonary





PECARN Conduct multi-institute research
into the prevention and
management of acute illnesses
and injuries in youth and
children.





EMNet Respiratory and allergy
emergencies; health policy and
other public health projects.






CCC = clinic coordinating center; DCC = data and coordinating center; EMNet = Emergency Medicine Network; NETT = Neurolog-
ical Emergencies Treatment Trials; NINDS = National Institutes of Neurological Disorders and Stroke; PECARN = Pediatric Emer-
gency Care Applied Research Network; ROC = Resuscitation Outcomes Consortium; SDMC = Statistical and Data Management
Center.
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Table 2
Potential Problems, Solutions, Pros, and Cons Associated With Research in the ED Setting
Potential Problem Potential Solutions Pros Cons
Estimating eligible
participants
Pilot study Up-to-date estimate of available
participants; preview potential
study problems.
Significant investment for a small
number of participants.
Chart review Estimate number historically
available.










Treating staff know the patient. Not all staff aware of all studies; ED






Can often find subjects for
cohort studies in real-time.
Need a critical number of
studies ⁄ patients to keep staff
engaged. For clinical trials needing
intervention need more experienced





Familiar with studies; can
access and identify
participants in real time
outside of treatment team.
Funding for position requires large




Alerts researchers to potential
participants in ED through
trauma activations, stroke
codes, etc.





Treatment team made aware of
trial prior to performing a
procedure ⁄ ordering tests.
Could delay treatment for people not





Alerts can be triggered on a
variety of ‘‘trigger pints’’
including orders or results.
Not available in all EHRs and requires
expensive programming. Alerts




Alerts can be triggered on a
variety of ‘‘trigger pints’’
including orders or results and
be sent directly to research
team for further screening.
Requires institutional IT costs, foreign






Allows for consent by someone
other than patient.
May not be available; treating team




Time to spend with patient
and ⁄ or LAR.
Cost and availability; may require
multiple studies to be cost-effective.
In-field cell phone Limits time to first contact of
LAR
No guarantee of contact, could take
focus away from treatment time.
EFIC Allows for treatment when
patient or LAR consent in
unavailable.







Allows for easy execution of
research.
Limits the number of outcomes and






errors ⁄ violations; guarantees
knowledge of protocol
specifics.
Large start-up cost of new networks;
may require a large number of trials






Alleviates issues related to
transportation.





Obtains follow-up information. Local physician must be included in











Obtains follow-up information. Requires cooperation of follow-up





Obtains follow-up information. Costly to trial.
1106 Cofield et al. • EM CLINICAL TRIAL RECRUITMENT AND RETENTION
available for enrollment into their studies, they should
focus on specific strategies to enhance recruitment into
their trials. Recruitment into EM clinical trials has three
important elements: identification, consent and enroll-
ment, and implementation.
Identification of Participants
A critical hurdle for clinical trials is the lack of a timely
and efficient method for identifying participants who
meet inclusion and exclusion criteria for entry into pro-
spective studies. This is especially important in ED
patients, where time from presentation to the need for
treatment is short (e.g., cardiac catheterization, tissue
plasminogen activator for stroke, blood substitutes,
hypothermia for acute brain injury). Researchers cannot
expect busy clinical practitioners to screen and identify
eligible participants, nor can they expect participants to
answer study advertisements themselves.14,18–20 While
ED staff education and orientation are important, the
study is unlikely to be successful if it depends on treat-
ing physicians and staff to identify eligible participants.
The use of a research coordinator or a specific research
staff member who is either dedicated to reviewing cur-
rent patients in the ED or alerted to incoming patients
is essential to capture all eligible participants.21,22 While
research personnel are expensive, they can usually be
written directly into the funding mechanism and can
often be shared across multiple projects. Many aca-
demic EDs have invested in unfunded research person-
nel to develop a track record of success to help secure
future funding. Such research personnel can work
closely with clinical teams such as stroke and trauma
teams and can respond to specific clinical alerts
through central paging.23 For other conditions that do
not include clinical alert pages, students (undergradu-
ates, graduate, or postdoctoral fellows) have been suc-
cessfully utilized to be physically present in the ED to
screen prospective participants.24 However, the skill
and experience of these individuals to enroll patients
into interventional clinical trials is generally unproven.
Furthermore, there needs to be a sufficient volume of
patients and studies to justify the effort and cost of
their full-time presence.25 Creating a network to man-
age multiple studies within the same clinical center
may allow for the more efficient use of dedicated
personnel.4,5
Manually screening ED admission logs for potential
participants via medical records has been the method
by which most participants have been recruited. How-
ever, manual screening of ED admission logs is not
only inefficient and untimely, but also lacks the optimal
privacy intended in the Health Insurance Portability and
Accountability Act (HIPAA) for protected health infor-
mation. Given the desire to better identify and screen
participants, HIPAA-compliant electronic screening of
existing medical information has been developed and
used with some level of success.26–29 In a study using
clinical trial alerts within an electronic health record
(EHR), investigators were able to double enrollment.28
In this example, an EHR triggered an alert to the
patient’s physician when study criteria matched the
patient’s medical record. While the doubling of enroll-
ment was significant, the system was still inefficient and
required the physician to be actively logged on to the
patient’s chart before any alert would fire, and once the
alert was sent, the physician still had to call study inves-
tigators for the patient to be considered. To be success-
ful in emergency research, alerts from EHRs must be
timely and allow for programmed alerts directly to
investigators so that the enrollment of participants does
not depend on practitioners to notify the investigators.
There are existing notification programs that allow for
real-time notification based on Health Leven Seven
data. These software programs allow for instant notifi-
cation to investigators26 and have been used success-
fully to recruit participants in single institutions and
small networks.30 Overcoming data sharing and data
management concerns could make these viable systems
in large networks as this technology evolves.
Other ways to help remind or alert staff would be to
include reminders on procedure kits for studies involv-
ing particular procedures or hard stops on orders such
as x-rays or magnetic resonance imaging. The latter
was used successfully at some centers to remind staff
Table 2
(Continued)
Potential Problem Potential Solutions Pros Cons
Shorten follow-up
time
Less likely to lose people. Limits to short-term endpoints.
Use hard
endpoints like death
Can follow-up with death
registries (SSDI, NDI).







engaged in trail and offers
reminders of visits; allows
for troubleshooting of
potential barriers prior to a
missed visit.
Cost and time involved can be
high depending upon number
of participants; must obtain IRB
approval for all participant
contact and materials.
EFIC = exception from informed consent; EHR = electronic health record; HIPAA = Health Insurance Portability and Accountability
Act; HL-7 = Health Level Seven; IT = information technology; LAR = legally authorized representative; NDI = National Death
Index; SSDI = Social Security Death Index.
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to enroll participants into the National Emergency
X-Radiography Utilization Study (NEXUS), where cleri-
cal staff at most centers could not order radiographs
until the NEXUS imaging form was received as part of
the order.31,32 For simple prospective cohort studies,
having dedicated order sheets and documentation
sheets that are built into the clinical workflow helps
with compliance and enrollment. This is particularly
true when using an EHR with dedicated order sets and
documentation templates.
There are several examples where ED networks can
identify and enroll participants into large databases for
cohort studies. These include the National Center for
Infectious Diseases and Centers for Disease Control
EMERGEncy ID NET, for infections, and the Multicenter
Airway Research Collaboration (MARC), originally for
emergency asthma care, which is now the Emergency
Medicine Network (EMNet), that includes MARC, the
National ED Inventories (NEDI), National ED Safety
Study (NEDSS), and ED 24-hour Research Network
(ED24).33,34 Most of these types of networks have been
successful in using the above screening techniques, but
are not funded well enough to handle the complexity and
treatment intervention as part of a clinical trial. Better
funding and staffing of these existing networks may
allow more trials to be done quickly in EM, given their
proven ability to screen and recruit.
Consent and Enrollment
The time frame available to recruit participants in EM
clinical trials is often far shorter than that for standard
trials.35 The unique time pressures affect the consent
and enrollment process, with the further caveat that the
patient may not be able to consent due to neurologic
impairment accompanying the acute disease. Consent
by a legally authorized representative of the patient is
an option in these settings and is governed by various
state laws and corresponding institutional review
boards (IRBs). However, EM clinical trials are still faced
with problems seeking consent when the family and ⁄ or
the patient may not be available to consider participa-
tion in a clinical trial.35 Furthermore, the providers and
investigators seeking the consent often have no estab-
lished relationship with the family or patient. This rela-
tionship and trust are what many potential participants
depend on when making medical decisions, including
whether to participate in clinical trials.36–38 Those
obtaining consent in the ED can be aided by aligning
themselves with members of a treatment team for sup-
port. This includes getting treating physicians involved
and using specially trained social workers or trauma
counselors. Social workers and trauma counselors have
been helpful in obtaining consent for organ donations;
however, availability and cost-effectiveness of such per-
sonnel will vary with the size and type of institution.39
Although time is short, involving caregivers with exist-
ing medical relationships, such as primary care physi-
cians, can be helpful.40
Other studies have successfully used different tech-
niques to improve enrollment time. In the Field Adminis-
tration of Stroke Treatment–Magnesium (FAST-MAG)
pilot trial, emergency medical technicians (EMTs) carried
dedicated study cell phones for physician-investigator
phone elicitation of consent in the out-of-hospital set-
ting.41 The study found that use of the cell phone during
EMT prehospital treatment allowed for initiation of
study procedures over 100 minutes sooner than prior
trials than when consent was obtained after hospital
arrival.
When informed consent is not possible, exception
from informed consent has been used successfully to
enroll participants into research in the prehospital and
ED setting.42,43 While somewhat controversial, federal
regulations (FDA final rule 21 CFR 50.24) allow for
enrollment of participants into studies without prior
consent when a number of very specific conditions are
met.44 However, even if consent is waived before
enrollment, notification must be done and consent
obtained from the patient or legal authorized represen-
tative as soon as possible after the intervention. Such
studies are also required to follow additional guidelines
including requirements for community consultation and
public disclosure before, during, and after the study.
Implementation of Research Protocol
When implementing trials in the ED, investigators need
to make sure the trial and intervention are not overly
complex and can be started quickly, if not completed in
the ED. Complex trials with prolonged and complex
screening protocols can be difficult to implement even
if they are well funded. The impact and time required
for what appears to be simple or routine intervention
should not be underestimated. Accordingly, most suc-
cessful large trials in EM have been prospective cohort
studies and not clinical trials.4–6 There are few complex
trials that can be done in the ED. These trials often
require special environments and investigators to com-
plete them, making widespread implementation diffi-
cult,45 and it is thus important to learn from relatively
simple trials completed in the ED.46–48 The intervention
should be simple or at least familiar for ED personnel
to carry out. Cardiac thrombolysis trials are an example
of how simple studies can rapidly recruit and complete
the implementation of the trial in the ED.49 As clinical
trials become more complex, they become more diffi-
cult to complete. In addition to the increased time and
cost of personnel training, the likelihood of protocol
violations increases with complexity.14 That risk can be
minimized with strict oversight by specific study coordi-
nators,22 but it requires a 24 ⁄ 7 presence for enrollment.
Paying teams to be on call to come in and care for
patients is a solution, but it is a costly solution that
requires a critical mass of ongoing trials. Networks
such as NETT, PECARNS, ROC, and EMNet have
addressed this critical mass by having a large number
of ongoing studies with dedicated infrastructure and
resources such as dedicated coordinators, collabora-
tive teams of investigators, primary administrative
coordinating centers, and central data collection and
management.
To ensure that the ED operational perspective is
included in the trial design, investigators should work
with ED staff and include an ED investigator early in
the protocol development. This will ensure that pro-
posed trials are designed optimally for the ED environ-
ment and that only key interventions and data points
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are included. For example, NETT has an executive com-
mittee and steering committees that determine the suit-
ability of trials in the ED environment. They help to
guide investigators during the trial design in an effort
to maximize study efficiency.4
Finally, engaging EM staff and giving them some
ownership over the trial (as co-investigators or with
related potential publication opportunities) is an impor-
tant way to improve successful implementation.14 Also,
providing nonresearch clinical staff with feedback and
thank you cards regarding patients they cared for in
the study help develop awareness and good will for the
trial within the ED.
RETENTION
Recruitment of participants is clearly a major hurdle
for EM clinical trials, but if participants are enrolled
and do not complete follow-up, attrition and bias
become factors that affect study interpretation and
eventual value. Attrition is defined as loss of numbers
due to resignation or death and is problematic in clini-
cal trials. Bias in terms of medical research refers to a
systematic situation that could not be remedied by
repeating a study over and over again. Attrition can
contribute to bias when participants are not lost ran-
domly, but reflect participants who have certain char-
acteristics that sustain better or worse outcomes.50–52
While randomization and intention-to-treat analysis
should address issues due to termination, they cannot
account for nonrandom treatment termination. For
example, participants in one treatment could consis-
tently feel so ill as a result of drug adverse effects that
they withdraw from the study at a higher rate than
another treatment group.
A key retention issue is time to follow-up of partici-
pants. Clearly, the longer the follow-up, the more par-
ticipants will be lost. Selection of a short-term outcome
(e.g., survival to hospital discharge) can alleviate some
attrition, but concise short-term outcomes are not
the focus of many trials. When long-term outcomes are
needed, clear concise outcomes like death can often be
accurately ascertained through the National Death
Index and Social Security Death Index, even when par-
ticipants appear lost to follow-up.30
Due to the nature of acute conditions, not everyone
presenting to the ED lives in the immediate area and is
available for follow-up care. Some may be visiting and
live out of state or the even out of the country; others
may be transient by nature, and over time people move.
If a study is multicenter, there may be an opportunity
for patients to have follow-up at another site. If partici-
pants need to make study-specific visits, consideration
should be made for participants who have physical and
logistical difficulties returning for follow-up. Further-
more, the time and costs associated with return visits
are key reasons for attrition and failure to recruit.53
If participants are compensated for transportation costs
and their visits are at no cost, they are more likely to
remain in the study.54
Other predictors of attrition include older age, male
sex, lower education attainment, functional impairment,
poorer cognitive performance, lower verbal intelligence,
greater comorbidities, and worse physical health.55
Some examples of attritional factors in other NIH studies
illustrate specific examples. The Baltimore Longitudinal
Study on Aging is a longitudinal study initiated in 1958
to study physiologic, sociologic, and psychological
changes with aging. Age, education, and distance from
the center have the strongest association with attrition.
Participants who lived 500 miles or more from the study
center, were over 70 years of age, had less than a bache-
lor’s degree, had poor perceived health, and ⁄ or had a
greater probability of dropping out.56
Despite attempts to minimize it, attrition will occur.
Among large population-based epidemiology studies
of older adults, attrition rates over 20% are frequently
reported for those with multiple follow-up interviews.
Among post–myocardial infarction patients, a mean
withdrawal rate of 21% has been reported in longitu-
dinal studies.57–59 It is implied that attrition of 5% or
less is unlikely to lead to bias, but that >20% poses
serious risks to study validity.60 Perhaps of most rele-
vance to EM clinical trials are the NINDS stroke trials
that have shown how retention may be less of an
issue for participants with more acute and severe
strokes who stay locally for care. The Specialized Pro-
gram of Translational Research in Acute Stroke,
funded by cooperative agreements from NINDS, is a
network of eight centers all running unique prospec-
tive EM clinical trials in major medical centers that
serve diverse populations.61 Since 2002, seven of these
centers have published results, with five of the seven
having postdischarge follow-up of 90 days.41,62–65 All
of the studies report high levels of follow-up at
3 months.
Factors that can help decrease attrition include
informed consent that clearly conveys the full commit-
ment required for participation in the trial; strong rela-
tionships between a study coordinator, care providers,
and the participants; and consistency among research
assistants in maintaining contact with the participants
they have recruited.66 The use of patient-centered tech-
niques such as videotapes or parsimonious question-
naires that are not overly time-consuming and impart
something interesting and of value to the participants
can be helpful. The Women’s Health Initiative is a study
focused on the prevention of morbidity and mortality in
declining quality of life in older women from diverse
backgrounds. Issues of diversity and understanding
clinical trials were essential. Basic communication
and listening skills were studied, and strategies to
improve retention were implemented, including careful
data monitoring and feedback to centers, intensive
staff training, psychological support, and educational
workshops.67,68
Participants should have follow-up and outcome
assessments conducted at routine clinic visit times if
possible. Office staff should be in close contact with
participants and record telephone follow-ups in a log,
keeping track of best times to contact the patient.54
While it is generally ideal to have follow-up conducted
in a controlled and consistent manner, participants
may be seen by local physicians and have standard of
care tests and assessments done remotely. This has
been made easier with guidance from the Office of
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Human Research Protections, which allows these
centers to cooperate with follow-up requirements
and not become technically engaged in research
and thus bound by other IRBs and institutional
subcontracts.39,69
SUMMARY
The obstacles involved with recruitment and retention
in emergency clinical trials are clear, and while we have
outlined the best available strategies to address them,
many of these are neither proven with evidence nor
likely to work in all settings. Nonetheless, EM research-
ers will have to develop such strategies to demonstrate
that they can recruit and retain patients. This is a neces-
sary component of an application to receive funding
and participate in EM trials and networks.
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